Teva
GenericsTeva is a generic drug manufacturer focused on Cardiovascular, Respiratory, Neurology. Key products include MICAFUNGIN.
FDA Novel Drug Designations
(2016-2018)Teva at a Glance
- Fast trial execution (18 months median completion)
Teva's Key Drugs
Teva's core commercial portfolio centers on FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE, OLANZAPINE AND FLUOXETINE HYDROCHLORIDE, NAPROXEN AND ESOMEPRAZOLE MAGNESIUM, spanning Cardiovascular and Respiratory — its most strategically important drugs approved in the last 15 years.
Hay Fever
Major Depressive Disorder
Osteoarthritis
Osteoarthritis
Obesity
Teva's Recent FDA Approvals
Teva secured 7 new FDA approvals for novel drugs (NDA/BLA) in the last two years.
Teva's Therapeutic Areas
Teva's approved drugs and pipeline span 5 therapeutic areas, led by Cardiovascular and Respiratory, across 1 biologic and 22 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
Teva's Top Competitors
Teva's closest competitors by therapeutic-area and drug-target overlap include Bayer, Pfizer, and Novartis. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
Teva Pipeline Snapshot
Teva has 102 active clinical programs from ClinicalTrials.gov — 60 Phase 3, 13 Phase 2 and 29 Phase 1.
Phase 3 Readout Calendar Pro
1 Phase 3 trial with confidence-graded primary completion dates.
Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE leads revenue
- • 5 key drugs tracked
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 2/4 completed
- • Speed: 18 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (39)
Discontinued (20)
Company Info
- First Approval
- 1948-10-12
- Latest
- 2026-06-23
- Applications
- 1345
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges